

Breast Cancer Tumor Markersⁱ

DIAGNOSIS	RECOMMENDED		NOT RECOMMENDED
	Test name	Purpose	Test
Newly Diagnosed Primary Invasive	<ul style="list-style-type: none"> ER/PgR test 	<ul style="list-style-type: none"> To predict response to endocrine treatment in adjuvant setting 	-
	<ul style="list-style-type: none"> HER2 test 	<ul style="list-style-type: none"> To predict response to trastuzumab and predict response to anthracycline-based adjuvant therapy 	
Metastatic	<ul style="list-style-type: none"> ER/PgR test 	<ul style="list-style-type: none"> To predict response to endocrine treatment in metastatic setting 	<ul style="list-style-type: none"> Do not use CA 15-3 and CA 27.29 alone Do not use CEA alone
	<ul style="list-style-type: none"> HER2 test 	<ul style="list-style-type: none"> To predict response to trastuzumab in the metastatic setting 	
	<ul style="list-style-type: none"> CA 15-3 and CA 27.29 (in conjunction with diagnostic imaging, history and physical exam) 	<ul style="list-style-type: none"> To monitor during active therapy 	
	<ul style="list-style-type: none"> CEA (in conjunction with diagnostic imaging, history and physical exam) 	<ul style="list-style-type: none"> To monitor during active therapy 	
Newly Diagnosed Primary Invasive Node Negative and ER and/or PgR Positive	<ul style="list-style-type: none"> Oncotype DX™ 	<ul style="list-style-type: none"> To determine prognosis in women who will receive adjuvant tamoxifen 	Other multiparameter gene expression assays
	<ul style="list-style-type: none"> uPA and PAI-1 test 	<ul style="list-style-type: none"> To determine prognosis, guiding use of CMF-based adjuvant chemotherapy 	
Newly Diagnosed Primary Invasive Node Negative and ER and PgR Negative	<ul style="list-style-type: none"> uPA and PAI-1 test 	<ul style="list-style-type: none"> To determine prognosis, guiding use of CMF-based adjuvant chemotherapy 	-
Recurrent Primary Invasive	<ul style="list-style-type: none"> HER2 test 	<ul style="list-style-type: none"> To predict response to trastuzumab and to predict response to anthracycline-based adjuvant therapy 	<ul style="list-style-type: none"> ER/PgR test Oncotype DX™ uPA and PAI-test
DCIS	n/a	n/a	ER/PgR test

ⁱ Table includes only tumor markers for which guideline recommend **selected** applications. Table does not include those tumor markers the guideline did **not recommend** in any application: DNA flow cytometry-based proliferation, p53, Cathepsin D, Cyclin E and other immuno-histochemically-based proliferation, proteomics, detection of bone marrow micrometastases, and circulating tumor cells.

This table is derived from recommendations in the ASCO 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. This table is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this table are voluntary. The practice guideline and additional information are available at <http://www.asco.org/guidelines/breasttm>. Copyright © 2007 by the American Society of Clinical Oncology. All rights reserved.